US › Healthcare

Lantern Pharma Inc (LTRN)

US · Healthcare · Biotechnology

$0.67+0.15%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-7.1M

EPS

$-0.28

EPS estimate

$-0.38

EPS came in at -0.28 against a street estimate of -0.38 — a beat of 26.3%.

Key statistics

Market cap

$10.6M

Forward P/E

0.0

P/B

9.74

Book value

$-0.25

EPS (TTM)

$-1.63

52-week high

$4.58

52-week low

$0.65

50-day MA

$1.85

200-day MA

$2.65

Beta

2.32

Analyst view

Analysts rate Lantern Pharma Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $17.50.

Shareholding

Insiders

17.36%

Institutions

19.30%

Largest institutional holders

Fund	Stake
Empery Asset Management, LP	5.64%
CM Management, LLC	3.35%
Vanguard Capital Management, LLC	2.85%
Renaissance Technologies Corp	1.95%
BIOS CAPITAL MANAGEMENT, LP	1.67%
Geode Capital Management, LLC	0.69%
Vanguard Fiduciary Trust Co	0.33%
Citadel Advisors Llc	0.32%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Lantern Pharma Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.